Medios AG Reports Strong Start to 2025 Financial Year

Medios AG, a key player in Europe's Specialty Pharma market, has posted a solid start to its 2025 financial year. First-quarter revenues grew by 6.2% to €484.7 million year-on-year, while EBITDA pre1 surged by 52.9% to reach €23.1 million, reflecting a margin improvement to 4.8%. Earnings per share climbed to €0.25 from €0.17 in the equivalent period of 2024, signaling robust growth potential.

CEO Matthias Gaertner highlighted strong performance across all segments, driven by a strategic focus on higher-margin products. EBITDA pre1 in the Pharmaceutical Supply segment increased 7.0% to €11.8 million. Meanwhile, slight revenue growth was seen in the Patient-Specific Therapies segment, reaching €55.8 million, with an EBITDA pre1 uptick of 6.4%.

Despite lower operating cash flow due to changes in net working capital, the company maintains an optimistic outlook for 2025, anticipating revenue and EBITDA pre1 growth of around 6% and 21.5%, respectively.